Background
Methods
Screening of eligible patients
Diagnosis and follow-ups
Clinical management and treatment strategies
Statistical analysis
Results
Characteristics and outcomes
Characteristics | Non- Fracture N = 234 (87.3%) | Fracture N = 34 (12.7%) | p* | ||
---|---|---|---|---|---|
N
| %, or mean ± SD |
N
| %, or mean ± SD | ||
Gender | |||||
Males | 141 | 60.3 | 19 | 55.9 | 0.030 |
Females | 93 | 39.7 | 15 | 44.1 | |
Age, years | |||||
Mean | 22.8 ± 15.2 | 23.5 ± 19.1 | 0.836 | ||
≤ 10 | 24 | 10.3 | 5 | 14.7 | 0.626 |
10–20 | 124 | 53.0 | 19 | 55.9 | |
> 20 | 84 | 35.9 | 10 | 29.4 | |
Stage of tumor a | |||||
IB | 4 | 3.2 | 0 | 0 | 0.112 |
IIB | 202 | 86.3 | 27 | 79.4 | |
III | 28 | 22.6 | 7 | 38.9 | |
Tumor size, mm2 | 148 | 363.7 ± 641.1 | 16 | 389.4 ± 845.9 | 0.907 |
Tumor location | |||||
Femur | 94 | 40.2 | 18 | 52.9 | 0.020 |
Tibia | 49 | 20.9 | 3 | 8.8 | |
Humerus | 16 | 6.8 | 10 | 29.4 | |
Fibula | 6 | 2.6 | 1 | 2.9 | |
Others b | 21 | 9.0 | 2 | 5.9 | |
Not Specified | 48 | 20.5 | 0 | 0.0 | |
Lung metastasis c | |||||
No | 159 | 67.9 | 17 | 50.0 | 0.039 |
Yes | 75 | 32.1 | 17 | 50.0 | |
Necrosis rate, % | |||||
< 90% (poor) | 41 | 31.1 | 13 | 44.8 | 0.351 |
≥ 90% (good) | 65 | 49.2 | 12 | 41.4 | |
No preoperative C/T d | 26 | 19.7 | 4 | 13.8 | |
Local recurrence | |||||
No | 183 | 78.2 | 26 | 76.5 | 0.820 |
Yes | 51 | 21.8 | 8 | 23.5 | |
Status until last follow up | |||||
No evidence of disease | 108 | 46.4 | 16 | 47.1 | 0.904 |
Alive with disease | 35 | 15.1 | 6 | 17.6 | |
Died of disease | 89 | 38.4 | 12 | 35.3 | |
Duration to recurrence, months | 41 | 23.1 ± 20.9 | 5 | 12.8 ± 9.4 | 0.084 |
Follow up duration, months | 234 | 68.0 ± 52.1 | 34 | 65.2 ± 57.7 | 0.362 |
Overall survival, months | 234 | 65.7 ± 48.9 | 34 | 56.4 ± 52.3 | 0.338 |
Progression free survival, months | 134 | 67.9 ± 52.0 | 20 | 65.2 ± 57.7 | 0.841 |
Disease-free survival, months | 108 | 87.1 ± 48.1 | 16 | 80.8 ± 55.1 | 0.667 |
Analyses of prognostic factors
Factor | Odds ratio | 95% CI | p (chi-square) |
---|---|---|---|
Gender (female vs. male) | 1.20 | 0.58–2.47 | 0.627 |
Poor necrosis rate (<90%) | 1.72 | 0.72–4.13 | 0.227 |
Lung metastasis | 2.12 | 1.03–4.38 | 0.043 |
Local recurrence | 1.10 | 0.47–2.59 | 0.820 |
Variable | OR | 95% CI |
p
|
---|---|---|---|
Fracture (reference: no fracture) | 0.88 | 0.41–1.86 | 0.731 |
Age group (reference: ≤ 10) | |||
10–20 | 1.52 | 0.63–3.67 | 0.355 |
>20 | 2.03 | 0.82–5.05 | 0.127 |
Gender (reference: male) | 0.80 | 0.48–1.34 | 0.420 |
Tumor stage (reference: IB) | |||
IIB | 1.68 | 0.17–16.75 | 0.658 |
III | 12.00 | 1.08–133.61 | 0.043 |
Tumor location (reference: fibula) | |||
Femur | 0.96 | 0.21–4.51 | 0.963 |
Tibia | 0.52 | 0.12–2.96 | 0.524 |
Humerus | 0.31 | 0.07–2.31 | 0.306 |
Necrosis rate < 90% (reference: ≥ 90%) | 2.11 | 1.01–4.44 | 0.048 |
Lung metastasis (reference: no) | 3.32 | 1.96–5.62 | 0.000 |
Local recurrence (reference: no) | 1.81 | 1.01–3.25 | 0.046 |